Abolis Biotechnologies, the French biotechnology company specialising in microbial systems and industrial-grade biotech applications, has launched MINE (Microbial INtelligence Explorer), a microbial-intelligence platform designed to help innovators, manufacturers and R&D teams understand, interpret and act on complex microbial systems. By connecting microbial and multi-omics data with experimental and industrial insight, the tool supports decisions across product innovation, process development and scale-up.

Bridging the gap between data and insight

Generating biological data is not the same as knowing how to use it. The challenge lies not only in identifying what microbes can do, but in understanding which biological mechanisms and parameters are relevant at the metabolic level and which development routes warrant further investigation.

MINE, developed with industry, brings together genomic exploration, multi-omics analysis and experimental interpretation. It helps teams examine how individual strains contribute to producing molecules of interest, understand interactions within complex microbial systems and identify levers for process optimisation. Built on an understanding of metabolic networks, it identifies the microorganisms, parameters and precursors to test, allowing teams to move from trial and error towards more considered experimental design and faster optimisation. By linking findings to technical and industrial constraints, it helps partners prioritise experiments, identify validation needs and focus resources.

From Microbiome Studio to MINE

The platform’s foundations were laid in Microbiome Studio, a machine-learning-enabled analytical platform born out of the Metapath project, an industrial programme supported by the French Government. Created for Abolis’ own programmes and refined through industrial collaborations, it was developed into MINE for external R&D and open-innovation teams. MINE aims to make microbial data accessible without requiring every decision-maker to be an omics or bioinformatics specialist.

Sylvia Julien, General Manager of the MINE Business Unit, said: “The challenge in microbial biotechnologies lies in the difficulty of integrating the various pieces of information and, therefore, to know which signals matter and which hypotheses deserve further testing for product development. MINE gives teams a clearer way to navigate that complexity, helping them focus experimental work on the questions most likely to move a programme forward.”

Linking microbial intelligence with scale-up

The launch extends Abolis’ ideation-to-scale model by connecting microbial intelligence with its capabilities in strain engineering, enzyme modelling, fermentation, bioprocess development and scale-up support, so partners can assess biological potential and industrial feasibility within the same programme. The tool supports work across pharma and healthcare, cosmetics and personal care, food, nutrition and agriculture, including ingredients, biotics, fermentation-derived products and bio-based alternatives.

Cyrille Pauthenier, Co-founder and CEO of Abolis, which was founded in 2014, commented that the platform “strengthens Abolis’ ability to support decisions before, during and beyond experimentation, connecting biological evidence wit  the realities of validation, process development and scale-up”. He added: “For our partners, that means a clearer route from microbial potential to an industrially relevant programme.”

For more information, visit:https://www.abolis.fr/

Digital issue: Please click here for more information